Skip to main content
Beth Israel Deaconess Medical Center
Primary menu
  • Home
  • Our Team
  • Research
  • Fellowship & Education
  • Publications
  • News and Archives

Retraction notice to "Screening for novel central nervous system biomarkers in veterans with Gulf War Illness" [Neurotoxicology and Teratology 61 (2017) 36-46].

Abou-Donia, Mohamed B, Lisa A Conboy, Efi Kokkotou, Eric Jacobson, Eman M Elmasry, Passent Elkafrawy, Megan Neely, Cameron R Dale Bass, and Kimberly Sullivan. 2025. “Retraction Notice to ‘Screening for Novel Central Nervous System Biomarkers in Veterans With Gulf War Illness’ [Neurotoxicology and Teratology 61 (2017) 36-46].”. Neurotoxicology and Teratology 107: 107423.
Publisher's Version
Last updated on 07/28/2025
PubMed

Selected Publications

  • Mistakes in therapeutic drug monitoring of biologics in IBD and how to avoid them
  • Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial).
  • Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
  • A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
  • Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis.
  • Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
More
Contact Us

330 Brookline Avenue

Boston, MA, 02215

Powered byOpenScholar®Admin Login